American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

uniQure N.V. (QURE)

$24.58 +8.26% NASDAQ: QURE · 15-min delayed

AMSTERDAM,
Public · NASDAQ: QURE
221 employees
Founded 1998

Visit website Follow

$2.7BMarket cap

$13.1MRevenue · FY2017

-$199.0MNet income

221Employees

QURENASDAQ

2014IPO

About uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1998
Type: Public · NASDAQ: QURE
Employees: 221
IPO date: Feb 5, 2014
Headquarters: PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: NL — outside the United States
Registered office: Amsterdam, NL
Legal entity ID: 724500RPCTZLFYJZ3S98

Source: GLEIF, the global Legal Entity Identifier registry · checked Aug 8, 2026. A US headquarters does not always mean US incorporation.

Is uniQure N.V. an American company? No. uniQure N.V. is incorporated in the Netherlands. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Registry IDs

Ticker: QURE Nasdaq
SEC CIK: 1590560
LEI: 724500RPCTZLFYJZ3S98
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show uniQure N.V.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/uniqure-nv/"><img src="https://americancompanies.com/badge/uniqure-nv.svg" alt="uniQure N.V. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow uniQure N.V. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2017: $13.1M
Net income: -$199.0M
Total assets: $824.9M
Market cap: $2.7B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: QURE

$24.58 +8.26%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$9.03 $70.59

52-week range

Market cap: $2.7B
Shares outstanding: 109.0M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Feb 5, 2014

uniQure N.V. (QURE) Stock Price

Reported a net loss of $199.0M in FY2017.
Trading 65% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review uniQure N.V..

Write a review

Newsroom

News about uniQure N.V.

3 Promising Genomics Stocks to Add to Your Portfolio Now Zacks Investment Research · 2026-10-30 · positive INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT GlobeNewswire Inc. · 2026-10-13 · negative UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights GlobeNewswire Inc. · 2026-09-30 · negative uniQure Plunges on Additional Data From Huntington's Disease Study Zacks Investment Research · 2026-09-30 · negative QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C. GlobeNewswire Inc. · 2026-09-29 · negative Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? Zacks Investment Research · 2026-09-03 · neutral

News & sentiment via Polygon.io

FAQ

uniQure N.V.: frequently asked questions

Is uniQure N.V. an American company?

No — uniQure N.V. is not an American company. uniQure N.V. is incorporated in the Netherlands. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Where is uniQure N.V. incorporated?

uniQure N.V. is legally incorporated in the Netherlands, according to its GLEIF legal-entity record.

Is uniQure N.V. traded on a US stock exchange?

Yes — uniQure N.V. trades under the ticker QURE on the NASDAQ. A US stock listing does not by itself make a company American — incorporation and ownership are what this page reports.

Is uniQure N.V. publicly traded?

Yes — uniQure N.V. is a publicly traded company. Its stock trades under the ticker symbol QURE on the NASDAQ.

What does uniQure N.V. do?

uniQure N.V. is an American Pharmaceuticals company in the Health & Beauty sector.

When was uniQure N.V. founded?

uniQure N.V. was founded in 1998.

Explore